GlobeNewsWire
17 Dec 2025, 12:30 UTC · 40w ago
Verdict
Headline leans bullish. We score CYTK +1.00.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
Which stocks this story touches
More positive than 98% of ticker scores this week
Received drug approval in China, triggered a $7.5 million milestone payment, and has a positive EMA opinion.
Near neutral — 92% of ticker scores this week are stronger
The company is commercializing the approved drug in China, but the news is primarily a catalyst for Cytokinetics.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 76% of relationship scores this week
[mutual] Cytokinetics and Sanofi have a license and collaboration agreement for the development and commercialization of MYQORZO in Greater China.
More positive than 35% of relationship scores this week
[a_to_b] Sanofi makes milestone payments and royalties to Cytokinetics for the rights to commercialize MYQORZO in Greater China.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
14h ago
+5.0%
Price agrees with the score
$65.14 vs $62.02 close before publication (Dec 16) · not market-adjusted
CYTK chart →
